AstraZeneca plc (AZN) Earns Neutral Rating from Credit Suisse Group

AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Credit Suisse Group in a report issued on Monday. They currently have a GBX 5,000 ($63.25) price target on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective would indicate a potential downside of 5.84% from the stock’s previous close.

AZN has been the subject of a number of other reports. Liberum Capital reiterated a “buy” rating and issued a GBX 5,100 ($64.52) target price on shares of AstraZeneca plc in a research note on Thursday, April 27th. Barclays PLC reiterated an “overweight” rating and issued a GBX 6,000 ($75.90) target price on shares of AstraZeneca plc in a research note on Friday, April 28th. Berenberg Bank lowered their target price on shares of AstraZeneca plc from GBX 5,500 ($69.58) to GBX 5,450 ($68.94) and set a “buy” rating for the company in a research note on Tuesday, February 21st. Deutsche Bank AG reiterated a “buy” rating and issued a GBX 5,500 ($69.58) target price on shares of AstraZeneca plc in a research note on Wednesday, March 15th. Finally, Societe Generale reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Thursday, March 23rd. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of GBX 5,171.80 ($65.42).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (LON:AZN) opened at 5309.9824 on Monday. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The stock’s market capitalization is GBX 67.22 billion. The stock’s 50 day moving average is GBX 5,087.18 and its 200 day moving average is GBX 4,684.86.

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Earns Neutral Rating from Credit Suisse Group” was first published by sleekmoney and is the sole property of of sleekmoney. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://sleekmoney.com/astrazeneca-plc-azn-earns-neutral-rating-from-credit-suisse-group/1919975.html.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/astrazeneca-plc-azn-earns-neutral-rating-from-credit-suisse-group/1919975.html

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *